Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS ...

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) ...

Click here and access our complete analysis report to understand the dynamics of Invivyd. NasdaqGM:IVVD Earnings Per Share Growth as at Mar 2025 Over the last year, Invivyd's total shareholder ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...

Invivyd Inc (NASDAQ:IVVD) is a biopharmaceutical company that makes antibody-based therapies for infectious diseases. The stock is up significantly so far in 2025 after the announcement of ...